| Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial.NeuroRehabilitation | PMID 34957954PMC8925123 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Preventive Effects of Boron-Based Gel on Radiation Dermatitis in Patients Being Treated for Breast Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Oncol Res Treat | PMID 34979503无 PMCID | 2022 | 0.90 | The study is a Phase III randomized controlled trial in oncology (breast cancer), but the intervention is a boron-based gel for preventing radiation dermatitis, not a drug intervention for cancer treatment. The endpoints are incidence of dermatitis, erythema, and desquamation after 14 days, which are categorical side-effect outcomes, not time-to-event efficacy endpoints (OS, PFS, DFS, etc.) as required. | 待处理 |
| Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study.Horm Res Paediatr | PMID 35417909PMC9533447 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Postoperative Vitamin Profile after Receiving a Novel Peripheral Parenteral Nutrition Solution: Multicenter Randomized Controlled Phase III Trial.Ann Nutr Metab | PMID 35439754无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D).Am J Nephrol | PMID 35462369PMC9254304 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND).Am J Nephrol | PMID 35462372无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.J Prev Alzheimers Dis | PMID 35542991无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.Neuroimage Clin | PMID 35878575PMC9421448 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.Technol Cancer Res Treat | PMID 35929135PMC9358559 | 2022 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).J Med Econ | PMID 35971655无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.J Prev Alzheimers Dis | PMID 36281683PMC9226274 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins.J Cardiovasc Pharmacol Ther | PMID 36420979无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials.Am J Nephrol | PMID 36450264PMC9909618 | 2022 | 0.85 | The record describes a Phase 3 randomized trial of a drug, but it is not an oncology study and its primary endpoint is safety, not a time-to-event efficacy measure. | 待处理 |
| Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease.Gac Med Mex | PMID 36657136无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial.PLoS One | PMID 34986178PMC8730423 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.PLoS One | PMID 35130291PMC8820628 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.PLoS One | PMID 35176038PMC8853539 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial.Ear Hear | PMID 34483247无 PMCID | 2022 | 0.95 | The study is a randomized phase III/IIIb clinical trial in human oncology patients with a drug intervention, but its primary efficacy endpoint is audiometric hearing threshold (a continuous safety/toxicity outcome), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or analysis via Kaplan-Meier/HR. | 待处理 |
| Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib.Dis Markers | PMID 35356064PMC8958089 | 2022 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Impact of Baseline and Trajectory of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus.Front Endocrinol (Lausanne) | PMID 35399955PMC8987353 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.Front Immunol | PMID 35493455PMC9044076 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature.Front Endocrinol (Lausanne) | PMID 35573994PMC9102803 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.J Cutan Med Surg | PMID 35354410无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| 23G Minimally Invasive Vitrectomy Combined with Glaucoma Drainage Valve Implantation and Phacoemulsification Cataract Extraction for Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy with Vitreous Hemorrhage.Comput Math Methods Med | PMID 35966245PMC9371887 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus.Front Endocrinol (Lausanne) | PMID 36034445PMC9402888 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study.J Clin Lipidol | PMID 35871058无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.Mol Genet Metab | PMID 35961250PMC10826456 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.Mol Genet Metab | PMID 36027721PMC10826424 | 2022 | 0.85 | This is a randomized Phase 2/3 trial in humans with results, but the study focuses on a non-oncology metabolic disorder (MPS II) and its primary endpoint is cognitive function change, not a survival, progression, recurrence, death, or closely related oncology efficacy outcome. | 待处理 |
| Variability of Target Volumes and Organs at Risk Delineation in Breast Cancer Radiation Therapy: Quality Assurance Results of the Pretrial Benchmark Case for the POTENTIAL Trial.Pract Radiat Oncol | PMID 36058618无 PMCID | 2022 | 0.95 | The record describes a pretrial quality assurance study on contouring variability for the POTENTIAL trial (a Phase III RCT in breast cancer), but it does not present any efficacy or survival outcome data from the randomized trial itself. | 待处理 |
| Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.Int J Chron Obstruct Pulmon Dis | PMID 36072608PMC9443998 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.Drug Des Devel Ther | PMID 36164414PMC9509011 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized study for dosimetric assessment and clinical impact of bone marrow sparing intensity-modulated radiation therapy versus 3-dimensional conformal radiation therapy on hematological and gastrointestinal toxicities in cervical cancer.J Cancer Res Ther | PMID 36412399无 PMCID | 2022 | 0.90 | The study is a randomized phase III trial in human cervical cancer, but it reports on hematological and gastrointestinal toxicities and dosimetric analysis, not on the required survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes. | 待处理 |
| Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.J Clin Lipidol | PMID 36402670无 PMCID | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial.PLoS One | PMID 36327320PMC9632806 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.Front Public Health | PMID 36408023PMC9670176 | 2022 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial.PLoS One | PMID 36374913PMC9662729 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.PLoS One | PMID 36454738PMC9714746 | 2022 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.Front Immunol | PMID 36713413PMC9881590 | 2022 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.Blood | PMID 34407545PMC8718628 | 2021-Dec-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.J Am Coll Cardiol | PMID 34915982无 PMCID | 2021-Dec-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.J Clin Oncol | PMID 34652968PMC8677904 | 2021-Dec-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial.J Korean Med Sci | PMID 34931494PMC8688341 | 2021-Dec-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.Lancet | PMID 33308425无 PMCID | 2021-Dec-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.J Headache Pain | PMID 34922436PMC8903667 | 2021-Dec-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.N Engl J Med | PMID 34587382PMC8522798 | 2021-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.N Engl J Med | PMID 34739194无 PMCID | 2021-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.N Engl J Med | PMID 34739196无 PMCID | 2021-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and Safety of Three WHO Prequalified (DTwP -HB-Hib) Pentavalent Combination Vaccines Administered As Per Iranian National Immunization Plan in Iranian Infants: A Randomized, Phase III Study.Indian Pediatr | PMID 34939580无 PMCID | 2021-Dec-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.Blood Adv | PMID 34507350PMC9153035 | 2021-Dec-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.Lancet | PMID 34774196PMC8584828 | 2021-Dec-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |